Skip to main content
 
 

An innovative approach to the treatment of Type 2 Diabetes and Obesity

 
 

A novel class of gut-targeted polymer therapies

 
 

The benefits of metabolic surgery without the risks

Mimicking the effect of bariatric surgery with an oral pill

Glyscend’s dynamic barrier approach seeks to provide the benefits of gastric bypass surgery and duodenal exclusion devices to type 2 diabetic, overweight, and/or obese patients without the need for an invasive surgery or procedure.

Our uniquely designed drugs, based on a polymer therapeutic platform, are taken orally and can non-invasively mimic the physiology of bariatric surgery.

Glyscend | Mimicking the effect of a bariatric surgery with a pill
Glyscend | Mimicking the effect of a bariatric surgery with a pill
Glyscend | Reducing or eliminating the burden of T2D
Glyscend | Reducing or eliminating the burden of T2D

Leveraging decades of experience in gastroenterology, metabolism, polymer chemistry, and drug development

Glyscend’s team has contributed to over 25 FDA-approved therapeutic products, many being first-in-class, including Byetta®, Bydureon®, Renagel®, and Welchol®.

Latest News

Press Release | June 3, 2024

Glyscend Doses First Patient in a Phase 2 Obesity Trial of GLY-200, a First-in-Class Oral Polymeric Drug Candidate for the Treatment of Metabolic Disease

Press Release | September 5, 2023

Glyscend Therapeutics Appoints Sapan A. Shah, Ph.D., Accomplished Industry Executive, as Chief Executive Officer

Close Menu

About Glyscend, Inc.

1812 Ashland Avenue, Suite 110
Baltimore, MD 21205, USA

600 Suffolk Street, Suite 250
Lowell, MA 01854-3643, USA